The University of Chicago Header Logo

Connection

Michael Becker to Adult

This is a "connection" page, showing publications Michael Becker has written about Adult.
Connection Strength

0.467
  1. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
    View in: PubMed
    Score: 0.036
  2. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
    View in: PubMed
    Score: 0.032
  3. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
    View in: PubMed
    Score: 0.028
  4. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.027
  5. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
    View in: PubMed
    Score: 0.025
  6. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
    View in: PubMed
    Score: 0.024
  7. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
    View in: PubMed
    Score: 0.023
  8. Trade-off in object versus spatial visualization abilities: restriction in the development of visual-processing resources. Psychon Bull Rev. 2010 Feb; 17(1):29-35.
    View in: PubMed
    Score: 0.022
  9. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
    View in: PubMed
    Score: 0.016
  10. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1111-6.
    View in: PubMed
    Score: 0.015
  11. Sex on the internet: furthering our understanding of men with online sexual problems. Psychol Addict Behav. 2004 Sep; 18(3):223-30.
    View in: PubMed
    Score: 0.015
  12. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
    View in: PubMed
    Score: 0.015
  13. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
    View in: PubMed
    Score: 0.010
  14. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018 04; 77(4):563-570.
    View in: PubMed
    Score: 0.010
  15. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
    View in: PubMed
    Score: 0.009
  16. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
    View in: PubMed
    Score: 0.009
  17. Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):372-378.
    View in: PubMed
    Score: 0.009
  18. Current Orthopaedic Surgeon Practices for Nonarthroplasty Treatment of Osteoarthritis of Adult Hip and Knee. J Surg Orthop Adv. 2015; 24(4):213-20.
    View in: PubMed
    Score: 0.008
  19. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
    View in: PubMed
    Score: 0.007
  20. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1745-52.
    View in: PubMed
    Score: 0.007
  21. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.007
  22. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012 May; 71(5):614-23.
    View in: PubMed
    Score: 0.007
  23. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
    View in: PubMed
    Score: 0.006
  24. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
    View in: PubMed
    Score: 0.006
  25. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
    View in: PubMed
    Score: 0.006
  26. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
    View in: PubMed
    Score: 0.005
  27. Neurodevelopmental impairment and deranged PRPP and purine nucleotide synthesis in inherited superactivity of PRPP synthetase. Adv Exp Med Biol. 1989; 253A:15-22.
    View in: PubMed
    Score: 0.005
  28. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
    View in: PubMed
    Score: 0.005
  29. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
    View in: PubMed
    Score: 0.005
  30. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
    View in: PubMed
    Score: 0.005
  31. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988 Sep; 85(3):383-90.
    View in: PubMed
    Score: 0.005
  32. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am. 1988 Aug; 14(2):377-94.
    View in: PubMed
    Score: 0.005
  33. The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol. 2008 Aug; 20(8):726-31.
    View in: PubMed
    Score: 0.005
  34. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
    View in: PubMed
    Score: 0.005
  35. Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme. Arthritis Rheum. 1986 Jul; 29(7):880-8.
    View in: PubMed
    Score: 0.004
  36. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006 Apr; 60(4):408-14.
    View in: PubMed
    Score: 0.004
  37. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.004
  38. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.004
  39. Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul; 48(7):2036-41.
    View in: PubMed
    Score: 0.004
  40. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology. 2002 Oct; 123(4):1020-5.
    View in: PubMed
    Score: 0.003
  41. Mutations of the serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic pancreatitis. Am J Gastroenterol. 2002 May; 97(5):1133-7.
    View in: PubMed
    Score: 0.003
  42. Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr; 99(4):495-511.
    View in: PubMed
    Score: 0.003
  43. Hip involvement in ankylosing spondylitis. Arthritis Rheum. 1976 Jul-Aug; 19(4):683-92.
    View in: PubMed
    Score: 0.002
  44. Regulation of purine nucleotide synthesis. Effects of inosine on normal and hypoxantine-guanine phosphoribosyltransferase-deficient fibroblasts. Biochim Biophys Acta. 1976 Jun 18; 435(2):132-44.
    View in: PubMed
    Score: 0.002
  45. Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb; 57(2):308-18.
    View in: PubMed
    Score: 0.002
  46. Recent advances in the identification of enzyme abnormalities underlying excessive purine synthesis in man. Arthritis Rheum. 1975 Nov-Dec; 18(6 Suppl):687-94.
    View in: PubMed
    Score: 0.002
  47. Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
    View in: PubMed
    Score: 0.002
  48. Increased purine nucleotide degradation in the central nervous system (CNS) in PRPP synthetase superactivity. Adv Exp Med Biol. 1989; 253A:9-13.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.